RxDoctor Payments Data

Daniel McHugh, MD

Interventional Pain Medicine · Antioch, TNNPI 1790766319

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.

$6,253in general payments, 2019–2025

Across 307 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$784
  • Collegium Pharmaceutical, Inc.$627
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$581
  • Lundbeck LLC$439
  • Pfizer$362
  • Boston Scientific$329
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,253 in reported general payments places this provider in the 60th percentile of 41 interventional pain medicine providers in Tennessee.

See all interventional pain medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$111,324
Medicare patients
262
Services billed
1,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen802$17,575
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen429$12,206
BelbucaBuprenorphine Hcl17$8,177
Xtampza ErOxycodone Myristate18$7,869
Gabapentin433$3,551
Fentanyl26$2,366
Lidocaine24$1,981
Celecoxib113$1,976
Pregabalin112$1,769
Nabumetone136$1,397
Morphine Sulfate ErMorphine Sulfate68$1,275
Tizanidine Hcl115$1,169
Diclofenac Sodium50$980
Oxycodone Hcl51$831
Tramadol Hcl100$602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$627$16,04735 claims
Hikma Pharmaceuticals USAMorphine Sulfate$18$41022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 41 interventional pain medicine providers in Tennessee.

Other interventional pain medicine in Antioch

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →